Clinical Trial Update: A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating an organ-preservation strategy using immune checkpoint blockade for primary colorectal or gastroesophageal cancer has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastroesophageal Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Cancer, Gastroesophageal Cancer | Phase 2 | Status: WITHDRAWN